Breaking News

Jubilant Biosys, Janssen Expand Drug Discovery Pact

By Kristin Brooks | February 19, 2014

Aims to advance programs in multiple disease areas

Jubilant Biosys, a Bengaluru based subsidiary of Jubilant Life Sciences, has expanded its drug discovery alliance with Janssen Pharmaceutica N.V. into multiple therapeutic areas. Jubilant Biosys will conduct most of the research in India and certain aspects at Jubilant Discovery Center in the U.S. The alliance was established in 2011 and aims to deliver preclinical candidates to Janssen.
 
The collaboration has been expanded to leverage Jubilant’s drug discovery capabilities on selected drug discovery targets to advance programs in multiple disease areas. Jubilant will provide research services and will deliver preclinical candidates to Janssen for potential development and commercialization. Jubilant will receive research funding, milestones and royalties, should assets progress into clinical development and commercialization.
 
“We are pleased to announce the expansion of the Janssen-Jubilant collaboration and look forward to discovering Novel Chemical Entities (NCEs) that address the unmet medical needs in these important disease areas," said Dr. Subir K. Basak, president, Jubilant Biosys (Global Drug Discovery Services). “Over the past several years, we have been strengthening our disease franchises from a scientific perspective, and this collaboration serves as a validation of those efforts. We look forward to a long, and mutually beneficial, partnership.”

Related Contract Manufacturing:

Related Compliance:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research